View Older Stories View More Recent Stories

Aug 1, 2024 06:25AM Greenwich LifeSciences (GLSI) Provides Update on Expansion of Flamingo-01 into Spain
Aug 1, 2024 06:00AM Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
Jun 26, 2024 07:33AM Greenwich LifeSciences (GLSI) to Rejoin Russell 2000 Index
Jun 26, 2024 07:33AM Greenwich LifeSciences Set to Join Russell 2000 Index Again
Jun 14, 2024 06:01AM Greenwich LifeSciences (GLSI) Announces 175K Private Placement at $14.30/sh
Jun 14, 2024 06:00AM Greenwich LifeSciences Announces $2.5 Million Private Placement
Mar 13, 2024 06:01AM Greenwich LifeSciences (GLSI) Extends Lock-up of Directors and Officers to June 30, 2025
Mar 13, 2024 06:00AM Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
Mar 12, 2024 06:00AM Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
Mar 12, 2024 06:00AM Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
Feb 27, 2024 06:01AM Greenwich LifeSciences (GLSI) Announces Flamingo-01 Phase III Clinical Trial Approved to Expand into Five EU Countries
Feb 27, 2024 06:00AM Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
Feb 22, 2024 06:01AM Greenwich LifeSciences (GLSI) Announces Flamingo-01 Manufacturing & Protocol Accepted by EU Regulators
Feb 22, 2024 06:00AM Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
Feb 22, 2024 06:00AM Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
Feb 14, 2024 06:00AM Greenwich LifeSciences (GLSI) Provides Update on Phase III Trial
Feb 14, 2024 06:00AM Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
Nov 21, 2023 06:01AM Greenwich LifeSciences (GLSI) Extends Lock-up of Directors and Officers to End of 2024
Nov 21, 2023 06:00AM Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
Dec 29, 2022 06:49AM Greenwich LifeSciences (GLSI) Issues Year End Update
Dec 29, 2022 06:48AM Greenwich LifeSciences Provides Year End Update
Dec 1, 2022 06:00AM Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
Aug 11, 2022 10:30AM Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
Aug 3, 2022 08:00AM Greenwich LifeSciences (GLSI) Provides Updates on Flamingo-01 Phase III Clinical Trial
Aug 3, 2022 08:00AM Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
Jul 28, 2022 06:00AM Greenwich LifeSciences Provides Financing Strategy & Corporate Update
May 23, 2022 07:04AM Greenwich LifeSciences (GLSI) Resumes $4.5M Share Buyback
May 23, 2022 07:00AM Greenwich LifeSciences to Resume Stock Repurchase Program
May 23, 2022 06:06AM Greenwich LifeSciences (GLSI) Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
May 23, 2022 06:00AM Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
Apr 20, 2022 06:10AM Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
Apr 19, 2022 06:21AM Greenwich LifeSciences (GLSI) Presents Phase IIb Data Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
Apr 19, 2022 06:21AM Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
Mar 3, 2022 09:19AM Greenwich LifeSciences (GLSI) Issues Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting
Mar 3, 2022 09:19AM Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting
Feb 3, 2022 06:00AM Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
Feb 1, 2022 06:03AM Greenwich LifeSciences (GLSI) Announces Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
Feb 1, 2022 06:00AM Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
Jan 24, 2022 06:01AM Greenwich LifeSciences (GLSI) Announces $10M Share Buyback, Extends Insider Lock-Up for 1 Extra Year
Jan 24, 2022 06:00AM Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
Dec 15, 2021 06:00AM Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
Dec 9, 2021 06:29AM Greenwich LifeSciences (GLSI) Reports 5 Year Data for GP2 Phase IIb Clinical Trial, Reveals Potential For New T Cell Platform Technology
Dec 9, 2021 06:29AM Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
Dec 8, 2021 07:00AM Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
Dec 7, 2021 06:34AM Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
Dec 6, 2021 07:15AM Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
Nov 18, 2021 06:00AM Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
Nov 17, 2021 06:00AM Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
Nov 11, 2021 06:00AM Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
Nov 10, 2021 07:07AM Greenwich LifeSciences (GLSI) Issues Clinical Update on Upcoming Phase III Trial, FLAMINGO-01
View More Recent Stories View Older Stories